Vortioxetine for depression in adults
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Major depressive disorder is a common mental disorder affecting a person's mind, behaviour and body. It is expressed as a variety of symptoms and is associated with substantial impairment. Despite a range of pharmacological and non-pharmacological treatment options, there is still room for improvement of the pharmacological treatment of depression in terms of efficacy and tolerability. The latest available antidepressant is vortioxetine. It is assumed that vortioxetine's antidepressant action is related to a direct modulation of serotonergic receptor activity and inhibition of the serotonin transporter. The mechanism of action is not fully understood, but it is claimed to be novel. Vortioxetine was placed in the category of "Other" antidepressants and may therefore provide an alternative to existing antidepressant drugs. OBJECTIVES: To assess the efficacy and acceptability of vortioxetine compared with placebo and other antidepressant drugs in the treatment of acute depression in adults. SEARCH METHODS: We searched Cochrane's Depression, Anxiety and Neurosis Review Group's Specialised Register to May 2016 without applying any restrictions to date, language or publication status. We checked reference lists of relevant studies and reviews, regulatory agency reports and trial databases. SELECTION CRITERIA: We included randomised controlled trials comparing the efficacy, tolerability, or both of vortioxetine versus placebo or any other antidepressant agent in the treatment of acute depression in adults. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the studies and extracted data. We extracted data on study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy, acceptability and tolerability. We analysed intention-to-treat (ITT) data only and used risk ratios (RR) as effect sizes for dichotomous data and mean differences (MD) for continuous data with 95% confidence intervals (CI). Meta-analyses used random-effects models. MAIN RESULTS: We included 15 studies (7746 participants) in this review. Seven studies were placebo controlled; eight studies compared vortioxetine to serotonin-norepinephrine reuptake inhibitors (SNRIs). We were unable to identify any study that compared vortioxetine to antidepressant drugs from other classes, such as selective serotonin reuptake inhibitors (SSRIs).Vortioxetine may be more effective than placebo across the three efficacy outcomes: response (Mantel-Haenszel RR 1.35, 95% CI 1.22 to 1.49; 14 studies, 6220 participants), remission (RR 1.32, 95% CI 1.15 to 1.53; 14 studies, 6220 participants) and depressive symptoms measured using the Montgomery-Åsberg Depression Scale (MADRS) (score range: 0 to 34; higher score means worse outcome: MD -2.94, 95% CI -4.07 to -1.80; 14 studies, 5566 participants). The quality of the evidence was low for response and remission and very low for depressive symptoms. We found no evidence of a difference in total dropout rates (RR 1.05, 95% CI 0.93 to 1.19; 14 studies, 6220 participants). More participants discontinued vortioxetine than placebo because of adverse effects (RR 1.41, 95% CI 1.09 to 1.81; 14 studies, 6220 participants) but fewer discontinued due to inefficacy (RR 0.56, 95% CI 0.34 to 0.90, P = 0.02; 14 studies, 6220 participants). The quality of the evidence for dropouts was moderate.The subgroup and sensitivity analyses did not reveal factors that significantly influenced the results.In comparison with other antidepressants, very low-quality evidence from eight studies showed no clinically significant difference between vortioxetine and SNRIs as a class for response (RR 0.91, 95% CI 0.82 to 1.00; 3159 participants) or remission (RR 0.89, 95% CI 0.77 to 1.03; 3155 participants). There was a small difference favouring SNRIs for depressive symptom scores on the MADRS (MD 1.52, 95% CI 0.50 to 2.53; 8 studies, 2807 participants). Very low quality evidence from eight studies (3159 participants) showed no significant differences between vortioxetine and the SNRIs as a class for total dropout rates (RR 0.89, 95% CI 0.73 to 1.08), dropouts due to adverse events (RR 0.74, 95% CI 0.51 to 1.08) and dropouts due to inefficacy (RR 1.52, 95% CI 0.70 to 3.30).Against individual antidepressants, analyses suggested that vortioxetine may be less effective than duloxetine in terms of response rates (RR 0.86, 95% CI 0.79 to 0.94; 6 studies, 2392 participants) and depressive symptoms scores on the MADRS scale (MD 1.99, 95% CI 1.15 to 2.83; 6 studies; 2106 participants). Against venlafaxine, meta-analysis of two studies found no statistically significant differences (response: RR 1.03, 95% CI 0.85 to 1.25; 767 participants; depressive symptom scores: MD 0.02, 95% CI -2.49 to 2.54; 701 participants). In terms of number of participants reporting at least one adverse effect (tolerability), vortioxetine was better than the SNRIs as a class (RR 0.90, 95% CI 0.86 to 0.94; 8 stu
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Cross-national epidemiology of DSM-IV major depressive episode
Bromet, E., Andrade, L. H., Hwang, I., Sampson, N. A., Alonso, J., de Girolamo, G., de Graaf, R., Demyttenaere, K., Hu, C., Iwata, N., et al. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-90 · Cited by 2,221
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Self-citationImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568
Self-citationInterpreting treatment effects in randomised trials
Guyatt, G. H., Juniper, E. F., Walter, S. D., Griffith, L. E., & Goldstein, R. S. (1998) · BMJ · doi:10.1136/bmj.316.7132.690 · Cited by 516
Grant, R. L. (2014) · BMJ · doi:10.1136/bmj.f7450 · Cited by 515
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Gartlehner, G., Hansen, R. A., Morgan, L. C., Thaler, K., Lux, L., Van Noord, M., Mager, U., Thieda, P., Gaynes, B. N., Wilkins, T., et al. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-11-201112060-00009 · Cited by 355
Research works printed but not linked: 55
- Baldwin, 2011, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment, European Neuropsychopharmacology, 21, S390, 10.1016/S0924-977X(11)70627-7 · doi:10.1016/s0924-977x(11)70627-7
- Baldwin, 2012, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD), European Neuropsychopharmacology, 22, 482, 10.1016/j.euroneuro.2011.11.008 · DOI
- Henigsberg, 2011, Efficacy and tolerability of multiple doses of LU AA21004 in an 8-week trial of adults with major depressive disorder, European Neuropsychopharmacology, 21, S393, 10.1016/S0924-977X(11)70632-0 · DOI
- Jacobsen, 2015, A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder, Journal of Clinical Psychiatry, 76, 575, 10.4088/JCP.14m09335 · DOI · Paper page
- Katona, 2012, A randomised, double-blind, placebo controlled, active-referenced study of the multimodal antidepressant Lu AA21004 in the treatment of elderly depressed patients, European Neuropsychopharmacology, 22, S258, 10.1016/S0924-977X(12)70388-7 · DOI
- Mahableshwarkar, 2013, A randomized, double-blind trial of 2.5mg and 5mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder, Current Medical Research and Opinion, 29, 217, 10.1185/03007995.2012.761600 · DOI · Paper page
- Jacobson W Olsen C Mahableshwarkar A Yinzhong C Keefe R Effect of vortioxetine on functional capacity in patients with major depressive disorder with self-reported cognitive dysfunction 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug - 1 Sept; Amsterdam Netherlands 2015 S460 · doi:10.1016/s0924-977x(15)30622-2
- Keefe, 2014, Efficacy of vortioxetine on cognitive function in patients with major depressive disorder: cognitive test performance results: from a randomized, double-blind, duloxetine-referenced, placebo-controlled, Neuropsychopharmacology, 39, S389
- Harrison J Assessment of cognitive dysfunction in patients with depression - which test is best? 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 29 Aug - 1 Sept; Amsterdam Netherlands 2015 S669 · doi:10.1016/s0924-977x(15)30957-3
- Wang, 2015, Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study, Current Medical Research and Opinion, 31, 785, 10.1185/03007995.2015.1014028 · DOI · Paper page
- Browning M Smith J Conen S Smallman R Buchbjerg J Larsen Kg Vortioxetine reduces BOLD signal during performance of the N-back task in subjects remitted from depression and healthy control participants 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S314 5 · DOI
- Conen S McKie S Smallman RP Dutta A Dawson Gr Smith J Effects of vortioxetine on resting-state activity in subjects remitted from depression and healthy controls 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S442 · doi:10.1016/s0924-977x(15)30593-9
- Jacobsen, 2015, Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction, Journal of Sexual Medicine, 12, 2036, 10.1111/jsm.12980 · DOI · Paper page
- Jacobsen, 2015, Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study, International Clinical Psychopharmacology, 30, 255, 10.1097/YIC.0000000000000081 · DOI · Paper page
- Haggstrom L Nielsen RZ Danchenko N Poulsen L A randomised, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment 26th European College of Neuropsychopharmacology, ECNP Congress; 2013 Oct 5-9; Barcelona, Spain 2013 S412 · DOI
- Haggstrom, 2013, Randomized, double-blind, study of vortioxetine versus agomelatine in adults with MDD after inadequate response to SSRI or SNRI treatment, European Psychiatry, 28, 3009
- Papakostas, 2014, Efficacy and tolerability of vortioxetine is independent of previous treatment in MDD patients switched after an inadequate response, European Neuropsychopharmacology, 24, S466, 10.1016/S0924-977X(14)70745-X · doi:10.1016/s0924-977x(14)70745-x
- American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM-III)
- American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R)
- American Psychiatric Association, 1994, .
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
- American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 10.1176/appi.books.9780890425596 · DOI · Paper page
- Baldwin, 2016, The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies, Journal of Psychopharmacology (Oxford, England), 30, 242, 10.1177/0269881116628440 · DOI · Paper page
- Barbui, 2004, "Wish bias" in antidepressant drug trials?, Journal of Clinical Psychopharmacology, 24, 126, 10.1097/01.jcp.0000115665.45074.0d · DOI · Paper page
- Bauer, 2008, Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study, European Psychiatry, 23, 66, 10.1016/j.eurpsy.2007.11.001 · DOI · Paper page
- Berhan, 2014, Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials, BMC Psychiatry, 14, 276, 10.1186/s12888-014-0276-x · DOI · Paper page
- Bull, 2002, Discontinuing or switching selective serotonin-reuptake inhibitors, Annals of Pharmacotherapy, 36, 578, 10.1345/aph.1A254 · doi:10.1345/aph.1a254 · Paper page
- Citrome, 2014, Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?, International Journal of Clinical Practice, 68, 60, 10.1111/ijcp.12350 · DOI · Paper page
- Citrome, 2016, Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed, Journal of Affective Disorders, 196, 225, 10.1016/j.jad.2016.02.042 · DOI
- Du Jardin, 2016, Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression, Psychopharmacology, 233, 2813, 10.1007/s00213-016-4327-5 · DOI
- Feighner, 1972, Diagnostic criteria for use in psychiatric research, Archives of General Psychiatry, 26, 57, 10.1001/archpsyc.1972.01750190059011 · DOI · Paper page
- Florea I Loft H Danchenko N Rive B Brignone M Merikle E Vortioxetine effects on overall patient functioning in patients with major depressive disorder 28th European College of Neuropsychopharmacology, ECNP Congress; 2015 Aug 29 to Sep 1; Amsterdam, Netherlands 2015 S436 · doi:10.1016/s0924-977x(15)30584-8
- Fu, 2015, The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis, Psychopharmacology, 232, 7, 10.1007/s00213-014-3633-z · DOI
- Gartlehner, 2012, How should primary care doctors select which antidepressants to administer?, Current Psychiatry Reports, 14, 360, 10.1007/s11920-012-0283-x · DOI
- Guaiana, 2013, Agomelatine versus other antidepressive agents for major depression, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008851.pub2 · DOI · Paper page
- Guy, 1970, Manual for the ECDEU Assessment Battery 2
- Hamilton, 1960, A rating scale for depression, Journal of Neurology, Neurosurgery and Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Koesters, 2013, Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials, British Journal of Psychiatry, 203, 179, 10.1192/bjp.bp.112.120196 · DOI · Paper page
- Li, 2016, The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials, Neuropsychiatric Disease and Treatment, 12, 523
- Meeker, 2015, The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis, Systematic Reviews, 4, 21, 10.1186/s13643-015-0001-y · DOI · Paper page
- Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
- National Institute for Health and Care Excellence, 2009, Depression in Adults. CG90
- Pehrson, 2016, Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission, CNS Spectrums, 21, 162, 10.1017/S1092852915000486 · DOI · Paper page
- Pigott, 2011, STAR*D: a tale and trail of bias, Ethical Human Psychology and Psychiatry, 13, 6, 10.1891/1559-4343.13.1.6 · DOI · Paper page
- The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014
- Saito, 2010, Evaluation of the DSM-IV and ICD-10 criteria for depressive disorders in a community population in Japan using item response theory, International Journal of Methods in Psychiatric Research, 19, 211, 10.1002/mpr.320 · DOI · Paper page
- Schueler, 2011, A systematic review of duloxetine and venlafaxine in major depression, including unpublished data, Acta Psychiatrica Scandinavica, 123, 247, 10.1111/j.1600-0447.2010.01599.x · DOI · Paper page
- Spitzer, 1978, Research diagnostic criteria: rationale and reliability, Archives of General Psychiatry, 35, 773, 10.1001/archpsyc.1978.01770300115013 · DOI · Paper page
- Stahl, 2015, Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine, CNS Spectrums, 20, 455, 10.1017/S1092852915000346 · DOI
- Thase, 2016, A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults, European Neuropsychopharmacology, 26, 979, 10.1016/j.euroneuro.2016.03.007 · DOI · Paper page
- Weinmann, 2008, Re-evaluation of the efficacy and tolerability of venlafaxine vs SSRI: meta-analysis, Psychopharmacology, 196, 511, 10.1007/s00213-007-0975-9 · DOI
- World Health Organization (WHO), 1992, The ICD-10 Classification of Mental and Behavioural Disorders
- Zhang, 2013, Preliminary study of patterns of medication use for depression treatment in China, Asia-Pacific Psychiatry: Official Journal of the Pacific Rim College of Psychiatrists, 5, 231, 10.1111/appy.12022 · DOI
- Zhang, 2015, The US Food and Drug Administration's perspective on the new antidepressant vortioxetine, Journal of Clinical Psychiatry, 76, 8, 10.4088/JCP.14r09164 · DOI
- Zorzela, 2014, Quality of reporting in systematic reviews of adverse events: systematic review, BMJ (Clinical Research Ed.), 348, f7668
Cited by
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
Cognitive impairment in depression: recent advances and novel treatments
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384
Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75
Baune, B. T., Sampson, E., Louise, J., Hori, H., Schubert, K. O., Clark, S. R., Mills, N. T., & Fourrier, C. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.07.092 · Cited by 62
What Is New about New Antidepressants?
Dubovsky, S. L. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000488945 · Cited by 37
Metadata
- Authors
- Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2017-07-05
- Volume
- 2017
- Issue
- 7
- Pages
- CD011520-CD011520
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1497985356
- Cited by
- 56
- References
- 27
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vortioxetine for depression in adults. https://app.cochat.ai/papers/10.1002/14651858.cd011520.pub2
- The paper
- Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017). Vortioxetine for depression in adults. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011520.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.